[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Waldenstrom Macroglobulinemia Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 135 pages | ID: W2C0620CEB5EN
VPAResearch

US$ 630.00 US$ 700.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Waldenstrom Macroglobulinemia ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Waldenstrom Macroglobulinemia disease clinical trials. The research work analyzes the ongoing Waldenstrom Macroglobulinemia clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Waldenstrom Macroglobulinemia treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Waldenstrom Macroglobulinemia clinical trials.

Scope of the Report-
  • Ongoing Waldenstrom Macroglobulinemia clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Waldenstrom Macroglobulinemia
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Waldenstrom Macroglobulinemia clinical trials
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Waldenstrom Macroglobulinemia Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Waldenstrom Macroglobulinemia Trials by Phase
3.2 Ongoing Waldenstrom Macroglobulinemia Trials by Type
3.3 Ongoing Waldenstrom Macroglobulinemia Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Waldenstrom Macroglobulinemia Trials
4.2 Top 10 Countries conducting Waldenstrom Macroglobulinemia Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Waldenstrom Macroglobulinemia Trials by Sponsor Type
5.2 Waldenstrom Macroglobulinemia Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Waldenstrom Macroglobulinemia Trials by year
6.2 Subjects Recruited for Waldenstrom Macroglobulinemia Trials by Phase
6.3 Subjects Recruited for Waldenstrom Macroglobulinemia Trials by Trial Type
6.4 Subjects Recruited for Waldenstrom Macroglobulinemia Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Waldenstrom Macroglobulinemia Trials- Phase
7.2 Ongoing Waldenstrom Macroglobulinemia Trials- Phase
7.3 Ongoing Waldenstrom Macroglobulinemia Trials- Phase
7.4 Ongoing Waldenstrom Macroglobulinemia Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

LIST OF FIGURES

Figure 1: Waldenstrom Macroglobulinemia- Clinical Trials by Country
Figure 2: Waldenstrom Macroglobulinemia- Clinical Trials by Phase of Development, 2018
Figure 3: Waldenstrom Macroglobulinemia- Clinical Trials by Status, 2018
Figure 4: Waldenstrom Macroglobulinemia- Clinical Trials by Type, 2018
Figure 5: Waldenstrom Macroglobulinemia- Clinical Trials Split by Region, 2000-2018
Figure 6: Waldenstrom Macroglobulinemia- Clinical Trials by Type of Economy, 2018
Figure 7: Waldenstrom Macroglobulinemia- Enrolment by Phase, 2018
Figure 8: Waldenstrom Macroglobulinemia- Enrolment by Trial Type, 2018
Figure 9: Waldenstrom Macroglobulinemia- Enrolment by Recruitment Status, 2018
Figure 10: Waldenstrom Macroglobulinemia- Clinical Trials by Sponsor Type, 2018
Figure 11: Waldenstrom Macroglobulinemia- Enrolment by Type of Sponsors
Figure 12: Waldenstrom Macroglobulinemia- Enrolment by Leading Sponsors

LIST OF TABLES

Table 1: Waldenstrom Macroglobulinemia- Clinical Trials by Sponsor Type, 2018
Table 2: Waldenstrom Macroglobulinemia- Clinical Trials by Economy Type, 2018
Table 3: Waldenstrom Macroglobulinemia- Clinical Trials by Region, 2018
Table 4: Waldenstrom Macroglobulinemia- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Waldenstrom Macroglobulinemia- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Waldenstrom Macroglobulinemia- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Waldenstrom Macroglobulinemia- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Waldenstrom Macroglobulinemia- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Waldenstrom Macroglobulinemia- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company


More Publications